Benefits and burdens of participation in a longitudinal clinical trial - Wikidata - wikimedia - TriplyDB

Benefits and burdens of participation in a longitudinal clinical trial

Benefits and burdens of participation in a longitudinal clinical trial

http://www.wikidata.org/entity/Q33905620

about

Enhancing HIV vaccine trial consent preparedness among street drug users Systematic review and meta-analysis to estimate potential recruitment to dementia intervention studies.A pragmatic analysis of vulnerability in clinical research.Appealing to altruism is not enough: motivators for participating in health services research.Equipoise and nonmedical risks.A MULTICENTER, LONGITUDINAL, INTERVENTIONAL, DOUBLE BLIND RANDOMIZED CLINICAL TRIAL IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS RESIDING IN REMOTE AREAS: LESSONS LEARNED FROM THE LATE CYTOMEGALOVIRUS PREVENTION TRIAL.Information that should be given to HIV cohort participants during ongoing research: the viewpoints of patient representatives and research professionals

P2860

Q30227101-7BEF0D67-8980-4A44-9480-21665A223F01 Q38202615-8423A82B-9981-4EA0-A102-3D3DF5B8057D Q38635385-9E6AF404-5EA3-480E-A883-9B65A3C1F3AB Q47970103-12C1A4EE-4B78-4E89-A81B-7141C964F67C Q48079934-C68780ED-7E44-4C86-AA12-A762A30C6A4D Q50901017-E5904FF6-1C2D-4D64-BCD5-BBFB7613FC88 Q56775915-74CC6217-C86E-4C84-A2EC-E831D6E9141F

P2860

Benefits and burdens of participation in a longitudinal clinical trial

http://www.wikidata.org/entity/Q33905620

description

2009 nî lūn-bûn

@nan

2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

name

Benefits and burdens of participation in a longitudinal clinical trial

@ast

Benefits and burdens of participation in a longitudinal clinical trial

@en

type

label

Benefits and burdens of participation in a longitudinal clinical trial

@ast

Benefits and burdens of participation in a longitudinal clinical trial

@en

prefLabel

Benefits and burdens of participation in a longitudinal clinical trial

@ast

Benefits and burdens of participation in a longitudinal clinical trial

@en

P1433

Q33905620-3E5CF3BD-FFCF-46E1-902E-24911EF03E26

P1476

Q33905620-8E841D1A-DF6B-4241-A67F-9B7ADA143D1B

P2093

Q33905620-68F146D7-3C0D-4A3C-B6A7-909861616FB6

Q33905620-AC82223F-4FF3-4E29-9A95-DEC9D10F8295

Q33905620-DE8270E5-402E-451B-95C9-ACB34CEE1C1B

P2860

Q33905620-2B2DBD15-D974-4E30-ABCB-0FBE919B2058

Q33905620-35FFFEF8-BAAB-4F05-B587-EF480C735F25

Q33905620-43EF60CB-3089-4FB9-AD96-6A4C4777DEA8

Q33905620-56F37C20-A8C8-4CB1-944B-61D564E74663

Q33905620-5C09A073-2538-4F39-816D-321375D2795E

Q33905620-5F9D091B-5587-4945-8E1F-D332568B6D25

Q33905620-8DD4CD94-59CC-4F58-9C4D-D949C79EE40A

Q33905620-9041BEBA-CE9E-4444-87BD-618981E7FFD6

Q33905620-A066A14F-E0C0-41AB-B901-7A0D0E6EBD4A

Q33905620-B36583A1-48B1-4F1A-BDB3-E76CA48AE3C1

P304

Q33905620-95ACB2E4-D18C-43FB-893A-9230A3608650

P31

Q33905620-2F4E7DDB-9EDA-425E-BE4D-D610E83EF521

P356

Q33905620-7C4A7891-A055-474D-97A9-BAE963C54217

P433

Q33905620-1CD0D7FA-DC5C-484C-ACA1-6DD598AF37F1

P478

Q33905620-486B6201-35B0-45A2-AEF8-33873739411A

P50

Q33905620-5F10D8FE-1D25-4D24-B52D-7CFCBD95D1CF

Q33905620-82EF42FC-A029-4068-8810-12BBDB894A9C

Q33905620-D5AB4BEF-0EE4-4799-87B2-35E02D08C67B

P577

Q33905620-4706CBCA-755D-4F2F-B550-38405C9B3625

P5875

Q33905620-D830E25C-6B4B-4783-B94C-3FB3DAD5186C

P698

Q33905620-20FA6B19-45C4-49F1-A00F-51C4D9D344D0

P932

Q33905620-85E77CF1-3914-4C31-9061-5C97B70C53E2

P356

JER.2009.4.3.89

P1433

Journal of Empirical Research on Human Research Ethics

P1476

Benefits and burdens of participation in a longitudinal clinical trial

@en

P2093

Benjamin Krohmal

http://www.w3.org/2001/XMLSchema#string

Jaime Lazovski

http://www.w3.org/2001/XMLSchema#string

Marcelo Losso

http://www.w3.org/2001/XMLSchema#string

P2860

A randomised trial of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients: the UK-Vanguard Study

Quality of informed consent in cancer clinical trials: a cross-sectional survey.

International ethical guidelines for biomedical research involving human subjects.

Ethical aspects of clinical trials: the attitudes of participants in two non-cancer trials.

Participation in a clinical trial: the patients' point of view.

The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT.

A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.

CD4 cell response to 3 doses of subcutaneous interleukin 2: meta-analysis of 3 Vanguard studies.

South Asian patients' views and experiences of clinical trial participation.

Quantitative analysis of ethical issues in phase I trials: a survey interview of 144 advanced cancer patients.

P304

89-97

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1525/JER.2009.4.3.89

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Ezekiel Emanuel

Christine Grady

P577

2009-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26812188

http://www.w3.org/2001/XMLSchema#string

P698

19754238

http://www.w3.org/2001/XMLSchema#string

P932

2883616

http://www.w3.org/2001/XMLSchema#string